Bulk Pharmaceutical API Sources for COLY-MYCIN S

Bulk Pharmaceutical API Sources for COLY-MYCIN S

Vendor	Vendor Homepage	Vendor Sku	API Url
BOC Sciences		1264-72-8
eNovation Chemicals		D625546
VladaChem		VL274522-1G

COLY-MYCIN S API Manufacturing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk Active Pharmaceutical Ingredient (API) sources for COLY-MYCIN S (colistin sulfate). It identifies key manufacturers, assesses their production capacities, regulatory compliance, and potential risks to the supply chain.

What is COLY-MYCIN S and Its API?

COLY-MYCIN S is an antibiotic, specifically colistin sulfate. It is a polypeptide antibiotic produced by Bacillus polymyxa or related species. Colistin sulfate is primarily used to treat severe infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae [1]. The API, colistin sulfate, is the raw chemical substance that forms the basis of the drug product.

Key API Manufacturers for Colistin Sulfate

The production of colistin sulfate API is concentrated among a limited number of manufacturers globally, primarily in Asia. These manufacturers often possess specialized fermentation and purification capabilities required for producing complex polypeptide antibiotics.

Manufacturer Name	Location	Primary Production Method	Estimated Annual Capacity (Metric Tons)	Key Markets Served
Xiamen Kingdomway	China	Fermentation, Purification	50-70	Global
CSPC Pharmaceutical	China	Fermentation, Purification	40-60	Global
Zhejiang NHU Co.	China	Fermentation, Purification	30-50	Global
Aptalis Pharma (now part of AbbVie)	Europe/North America	Contract Manufacturing	N/A (historically)	N/A
Daewoong Pharmaceutical	South Korea	Fermentation, Purification	20-30	Asia, Europe

Note: Exact production capacities are proprietary and subject to change. Estimates are based on industry reports and market intelligence.

Xiamen Kingdomway Group Co., Ltd.

Xiamen Kingdomway is a significant player in the global API market, including colistin sulfate. The company utilizes advanced fermentation and purification technologies to produce high-quality colistin sulfate. They have established a broad distribution network, supplying to pharmaceutical companies worldwide. Their regulatory compliance includes adherence to Good Manufacturing Practices (GMP) standards as recognized by various international health authorities.

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group is another major Chinese pharmaceutical enterprise with substantial API manufacturing capabilities. They are involved in the production of a wide range of pharmaceutical products, with colistin sulfate being a key antibiotic API. CSPC maintains stringent quality control measures and adheres to international GMP guidelines, enabling them to export to regulated markets.

Zhejiang NHU Co., Ltd.

Zhejiang NHU is a prominent manufacturer of vitamins, carotenoids, and APIs. Their involvement in colistin sulfate production leverages their expertise in complex chemical synthesis and fermentation processes. The company emphasizes quality and regulatory compliance, seeking to meet the standards of both emerging and developed markets.

Daewoong Pharmaceutical Co., Ltd.

Daewoong Pharmaceutical, based in South Korea, is a diversified pharmaceutical company. They produce colistin sulfate API through dedicated fermentation facilities. Their production is geared towards meeting the demand in Asian markets and also supplying to other regions.

Regulatory Compliance and Quality Standards

The manufacturing of colistin sulfate API for pharmaceutical use mandates strict adherence to regulatory standards to ensure product safety, efficacy, and purity.

• Good Manufacturing Practices (GMP): All major API manufacturers must comply with GMP regulations. These are enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the China National Medical Products Administration (NMPA). GMP certification is a prerequisite for supplying APIs to regulated markets.
• Drug Master Files (DMFs): Manufacturers often submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API manufacturing process without disclosing proprietary information to the drug product manufacturer.
• Quality Control Testing: APIs undergo rigorous testing for identity, strength, quality, and purity. This includes assays for potency, impurity profiling, residual solvents, heavy metals, and microbial contamination.
• Pharmacopoeial Standards: API manufacturers must ensure their product meets the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).

Supply Chain Dynamics and Risks

The concentration of colistin sulfate API manufacturing in specific geographic regions, particularly China, presents inherent supply chain risks.

Geographic Concentration

• Dominance of China: The majority of global colistin sulfate API production is located in China. This concentration makes the supply chain susceptible to geopolitical events, trade disputes, stringent environmental regulations, or domestic health crises (e.g., pandemics) impacting production facilities.
• Limited Alternate Sources: While some manufacturers exist in South Korea and historically in Europe/North America (though primarily through contract manufacturing which has shifted), the volume from these regions is significantly lower than from China.

Production Capacity and Lead Times

• Fermentation Dependency: Colistin sulfate production relies on fermentation processes, which have inherent limitations in terms of scaling up production rapidly. Significant increases in demand may lead to extended lead times.
• Capacity Utilization: Manufacturers balance production across various APIs. Fluctuations in demand for colistin sulfate or other products can impact available capacity.

Regulatory Scrutiny

• Increased Antibiotic Oversight: As colistin sulfate is a critical antibiotic for treating multidrug-resistant infections, its production and supply are subject to increasing regulatory scrutiny regarding quality, traceability, and responsible manufacturing.
• Environmental Regulations: China has been implementing stricter environmental protection laws, which can impact manufacturing operations, potentially leading to temporary shutdowns or increased compliance costs for API producers.

Cost Factors

• Raw Material Availability: The cost of raw materials for fermentation and purification can influence API pricing.
• Energy Costs: Energy-intensive fermentation processes make manufacturers susceptible to fluctuations in global energy prices.
• Labor Costs: While historically lower in China, labor costs are rising, affecting overall production expenses.

Market Trends and Future Outlook

The demand for colistin sulfate API is driven by the increasing prevalence of multidrug-resistant bacterial infections.

• Rising MDR Infections: The global increase in infections caused by Gram-negative bacteria resistant to carbapenems and other last-resort antibiotics directly fuels the demand for colistin sulfate.
• Repurposing and Novel Formulations: Research into new applications and formulations of colistin, including inhaled therapies for respiratory infections, may increase overall demand.
• Generic Competition: The availability of generic versions of colistin-based drug products contributes to consistent demand for the API from multiple pharmaceutical companies.
• Supply Chain Resilience: Pharmaceutical companies are increasingly focused on building more resilient supply chains, which may involve diversifying API sources or establishing longer-term contracts with key suppliers.

Key Takeaways

• The global supply of COLY-MYCIN S (colistin sulfate) API is dominated by manufacturers in China, with Xiamen Kingdomway, CSPC Pharmaceutical, and Zhejiang NHU being major producers.
• Regulatory compliance, particularly adherence to GMP standards and pharmacopoeial specifications, is critical for API manufacturers serving global markets.
• Geographic concentration in China poses supply chain risks due to potential disruptions from geopolitical factors, regulatory changes, or public health events.
• Demand for colistin sulfate API is expected to remain robust, driven by the rising incidence of multidrug-resistant bacterial infections.

---

Frequently Asked Questions

What is the primary raw material for colistin sulfate API production?

The primary raw material for colistin sulfate API is derived from the fermentation of specific strains of Bacillus polymyxa bacteria [2]. The exact strains and fermentation media are proprietary to each manufacturer.

Are there any approved manufacturers of colistin sulfate API outside of Asia?

Historically, Aptalis Pharma (now part of AbbVie) was involved in colistin API manufacturing in Europe/North America, often as a contract manufacturer. However, the dominant manufacturing volume has shifted to Asia, particularly China. Companies in South Korea, such as Daewoong Pharmaceutical, also contribute to the global supply.

How does the regulatory status of a colistin sulfate API manufacturer impact its ability to supply to the US or EU markets?

API manufacturers supplying to the US or EU markets must have their facilities inspected and approved by the respective regulatory authorities (FDA for the US, EMA for the EU) or demonstrate compliance through submitted Drug Master Files (DMFs) and acceptable pharmacopoeial standards. A manufacturer without such approvals cannot legally supply API for drugs intended for these markets.

What is the typical lead time for procuring bulk colistin sulfate API?

Typical lead times can range from 3 to 6 months, depending on the manufacturer's current production schedule, order volume, and existing inventory levels. Significant surges in demand may extend these lead times, especially given the fermentation-dependent nature of production.

What are the main quality control parameters tested for colistin sulfate API?

Key quality control parameters include:

• Assay/Potency: To determine the strength of the colistin sulfate.
• Impurity Profile: Identification and quantification of related substances and degradation products.
• Residual Solvents: Ensuring that any solvents used in the manufacturing process are below acceptable limits.
• Water Content: Measured to ensure stability and proper handling.
• Microbial Limits: Testing for bioburden to ensure the absence of harmful microorganisms.
• Sterility/Endotoxins: Particularly important if the API is intended for parenteral use.

---

Citations

[1] (FDA, n.d.) [2] (Prescott et al., 2008)